Erectile Dysfunction Clinical Trial
Official title:
A Multi-Center ,Randomized, Double-Blind, Placebo-Controlled, Dose-Exploring Study to Evaluate the Efficacy and Safety of TPN171H in China Male Patients With Erectile Dysfunction
Verified date | December 2021 |
Source | Vigonvita Life Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an exploratory clinical study to presume the optimum usage and dosage for a therapeutic confirmatory study by evaluating the efficacy and safety of TPN171H 5mg, 10mg, 20mg or placebo administered orally in patients with erectile dysfunction. In conclusions, Patients with erectile dysfunction (ED) were administered placebo, TPN171H 5mg, 10mg or 20mg 30 minutes to 4 hours before sexual intercourse for 8 weeks.
Status | Completed |
Enrollment | 255 |
Est. completion date | July 26, 2021 |
Est. primary completion date | July 26, 2021 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 22 Years and older |
Eligibility | Inclusion Criteria: - Male patients aged =22 with ED, defined as an inability to achieve or maintain a penile erection sufficient for satisfactory sexual intercourse, evident for at least 3 months; - Patients whose IIEF-EF domain score is < 26; - Patients in a stable, heterosexual relationship for at least 3 months and during the study; - Patients who are willing to stay away from any other medicines or treatments for ED during this study period; - Patients who are willing to have 4 or more attempts of sexual intercourse each month, demonstrated compliance with the study protocol, including drug administration, diary completion, and scheduled study visits, during the qualifying trial; - Patients who are willing to take proper contraceptive during the study and within 3 months after the study completed; - Patients who have voluntarily decided to participate in this study, and signed the informed consent form. Exclusion Criteria: - Patients with anatomical malformations of the penis; - Patients with primary hypoactive sexual desire; - Patients with ED, which is caused by any other primary sexual disorder, like hypopituitarism, hypothyroidism, or hypogonadism. - Patients with ED ,which is caused by spinal injury or have had a radical prostatectomy or other surgery ; - Patients who have a penile implant; - Patients who have a history of hypersensitivity to other PDE5 inhibitors or who have not responded to them; - Patients with the following cardiovascular disease: Myocardial infarction or stroke within the last 6 months; Unstable angina or angina occurring during sexual intercourse; New York Heart Association Class 2 or greater heart failure in the last 6 months; Uncontrolled hypotension (<90/60mmHg), or uncontrolled hypertension (=160/95mmHg); Orthostatic hypotension. - Patients administered with the following medications: Nitrate/Nitric oxide (NO) donors; Androgens, anti-androgen, trazodone; Agents that significantly affect the CYP3A4 intermediary metabolism. - Diabetic patients whose FBS is over 1.5 fold of normal value, or whose HbA1c exceeds 9%, or with diabetes complications, such as diabetic nephropathy, peripheral neuropathy; - Patients with hepatic or renal dysfunction as per the following: AST, ALT?2*ULN, serum creatinine exceeds 20% of the upper limit of normal value; - Patients with active gastrointestinal ulcers and bleeding disorders; - Patients who have a history of NAION, or with a known genetically degenerative retinopathy, including retinitis pigmentosa; - Patients who have a history of sudden decrease or loss of hearing; - Patient with a history of malignancy; - Patients with a major refractory psychiatric disorder or significant neurological abnormalities; - Patients with alcohol addiction or persistent abuse of drugs of dependence; - Patients who are participating or discontinued participation in the past 3 months from any other clinical trial, or are planning to father a baby or are in a relationship with a pregnant partner. - For other reasons besides the aforementioned cases, patient whose participation is deemed inappropriate due to clinically significant findings according to the medical decision of the principal investigator or the study personnel. |
Country | Name | City | State |
---|---|---|---|
China | Peking University Third Hospital | Beijing | Beijing |
China | The First Hospital of Jilin University | Changchun | Jinlin |
China | The Third Xiangya Hospital of Central South University | Changsha | Hunan |
China | The First Affiliated Hospital of Dalian Medical University | Dalian | Liaoning |
China | The First Affiliated Hospital of Fujian Medical University | Fuzhou | Fujian |
China | Guangzhou First People's Hospital | Guangzhou | Guangdong |
China | The First Affiliated Hospital of Anhui Medical University | Hefei | Anhui |
China | The First Affiliated Hospital of Nanchang University | Nanchang | Jiangxi |
China | Nanjing Drum Tower Hospital | Nanjing | Jiangsu |
China | Peking University Shenzhen Hospital | Shenzhen | Guangdong |
China | Second Affiliated Hospital of Suzhou University | Suzhou | Jiangsu |
China | Henan Provincial People's Hospital | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
Vigonvita Life Sciences | Shanghai Institute of Materia Medica, Chinese Academy of Sciences |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) at Week 8 | The primary efficacy variable was the change in the EF domain scores of the IIEF questionnaire from baseline, calculated by comparing total scores from questions 1-5 and 15 from the IIEF questionnaire . | baseline and 8 weeks | |
Primary | Change From Baseline in Question 2 of the Patient Sexual Encounter Profile (SEP) Diary at Week 8 in Percentage of Yes Responses | Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 2. "Were you able to insert your penis into your partner's vagina when you are trying to have sex ?" Data are presented as the mean percentage of yes responses per participant. | baseline and 8 weeks | |
Primary | Change From Baseline in Question 3 of the Patient Sexual Encounter Profile (SEP) Diary at Week 8 in Percentage of Yes Responses | Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 3. "Did your erection last long enough for you to have successful intercourse?" Data are presented as the mean percentage of yes responses per participant. | baseline and 8 weeks | |
Secondary | Change From Baseline to 4 Week and 8 Week Endpoint in International Index of Erectile Function (IIEF),Orgasmic Functions | Self-reported Orgasmic Functions over the past 4 weeks. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction), thus the 2 questions of the IIEF-OF domain range from 0 to 10. | baseline ,4 weeks and 8 weeks | |
Secondary | Change From Baseline to 4 Week and 8 Week Endpoint in International Index of Erectile Function (IIEF) ,Sexual Desire | Self-reported Sexual Desire over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-SD domain range from 0 to 10. | baseline ,4 weeks and 8 weeks | |
Secondary | Change From Baseline to 4 Week and 8 Week Endpoint in International Index of Erectile Function (IIEF),Intercourse Satisfaction | Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15. | baseline ,4 weeks and 8 weeks | |
Secondary | Change From Baseline to 4 Week and 8 Week Endpoint in International Index of Erectile Function (IIEF), Overall Satisfaction | Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10. | baseline ,4 weeks and 8 weeks | |
Secondary | Change From Baseline in Question 2 of the Patient Sexual Encounter Profile (SEP) Diary at Week 4 in Percentage of Yes Responses | Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 2. "Were you able to insert your penis into your partner's vagina?" Data are presented as the mean percentage of yes responses per participant. | baseline and 4 weeks | |
Secondary | Sexual Encounter Profile (SEP) Diary, Question 3 Change From Baseline to Week 4 in Percentage of Yes Responses | Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 3. "Did your erection last long enough for you to have successful intercourse?" Data are presented as the mean percentage of yes responses per participant. | baseline and 4 weeks | |
Secondary | Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) =26 at Week 8 | Assessed was the changes in the number of subjects whose IIEF domain score at the 8th week visit was =26. | baseline ,4 weeks and 8 weeks | |
Secondary | Subgroup analysis based on ED severity categories: severe,0-10; moderate,11-16; mild,17-25. | Subgroup analysis based on ED severity categories: severe,0-10; moderate,11-16; mild,17-25. | baseline ,4 weeks and 8 weeks | |
Secondary | Subgroup analysis based on the time intervals between meal and medication. | Subgroup analysis based on the time intervals between meal and medication. | baseline ,4 weeks and 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 |